- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Blox Labs Receives CSE Approval for Change of Business and Name Change to Sire Bioscience Inc.
Blox Labs Inc. (“Blox” or the “Company”) (CSE:BLOX, Frankfurt:BR1B, OTC:BLLXF) is pleased to announce that further to its news release dated August 29, 2019, the Company has completed all matters relating to its change of business, including receiving final approval from the Canadian Securities Exchange (“CSE”), completion of a name change to Sire Bioscience Inc. (“Sire”), and pursuant to a CSE bulletin, will commence trading on the CSE under the symbol “SIRE” on September 11, 2019.
Blox Labs Inc. (“Blox” or the “Company”) (CSE:BLOX, Frankfurt:BR1B, OTC:BLLXF) is pleased to announce that further to its news release dated August 29, 2019, the Company has completed all matters relating to its change of business, including receiving final approval from the Canadian Securities Exchange (“CSE”), completion of a name change to Sire Bioscience Inc. (“Sire”), and pursuant to a CSE bulletin, will commence trading on the CSE under the symbol “SIRE” on September 11, 2019.
The Company will also affect management changes in conjunction with the completion of the transaction.
On the listing date, the directors and officers of Sire will consist of:- Brian Polla, COO and director
- Jeff Zanini, CEO and director
- Sean McGrath, CFO
- Jerry Habuda, director
- Adrian Burke, director
- Brian Nugent, director
The Company has officially launched its new website at www.sirebioscience.com.
About Sire Bioscience Inc.
Sire is Canadian life sciences company with a focus on the cultivation, production and sale of industrial hemp. Sire is headquartered in Toronto, Ontario and it owns a 50-acre parcel of land, inclusive of a 160,000 sq. ft. state-of-the-art greenhouse, in Leamington, Ontario – a preeminent locale for hemp cultivation in Canada.
For additional information:
Sire Bioscience Inc.
Jeff Zanini, CEO
T: 416-262-0871
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
Source: www.thenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.